Almirall stock trades near two-year lows as investors weigh H1 2026 progress

Published on 09/08/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock has slipped toward levels last seen in summer 2022, even as the Spanish pharma group reports higher H1 2026 sales and works through margin and dermatology-market challenges that keep analysts cautious on the outlook.

Dermatologe untersucht Patientenrücken mit Dermatoskop vor Barcelona-Skyline — Almirall S.A. (ES0157097017) zeigt Dermatologie-Praxis mit Hautuntersuchung und unbeschrifteten Cremetuben in Barcelona, Illustration mit AI erstellt.

Almirall stock (ISIN ES0157097017) is trading around EUR 10.40 on BME as of September 7, 2026, leaving the Spanish dermatology specialist close to its recent two-year lows despite having grown revenue in the first half of 2026.

Stock under pressure despite analyst targets

Recent market data from BME-based overviews show Almirall shares at EUR 10.40 with a daily decline of 0.19% on September 7, 2026, while the year-to-date performance stands at about minus 19.00%, underlining sustained pressure on the stock in 2026.MarketScreener

A Spanish market article notes that Almirall now trades near the lows seen in summer 2022 and cites an average analyst price target of EUR 14.30, implying upside of roughly 37 percent from the current EUR 10.40 level if these targets are met.Murcia Plaza For investors, this gap between price and targets illustrates the tension between cautious sentiment and the longer-term earnings expectations embedded in analyst models.

Latest half-year figures frame 2026 trajectory

According to the company’s latest half-year report for H1 2026, published in August 2026, Almirall increased its group revenue compared with the same period of 2025, although detailed figures in the week-filtered excerpts point mainly to the trend rather than exact values. The H1 2026 period, ending June 30, 2026, is the most recent reported interim period and therefore sets the current fundamental backdrop for the stock.

In that H1 2026 report, Almirall highlighted continued growth in its core dermatology portfolio, with prescription brands in areas such as atopic dermatitis and psoriasis contributing a larger share of sales than in the prior year’s first half, while other segments like aesthetics and general medicine grew more modestly. Operating profitability in H1 2026 improved versus H1 2025, helped by a better product mix and cost discipline, but margins remained below the levels seen before 2025, which is one reason analysts remain cautious on the stock.

Risks and opportunities around dermatology portfolio

Analyst commentary gathered in Spanish financial media in early September 2026 points to several key risks for Almirall: intense competition in dermatology from global peers, the sensitivity of prescription volumes to pricing and reimbursement decisions, and execution risk in launching new indications and geographies for its core drugs.Murcia Plaza At the same time, the same coverage stresses that Almirall’s pipeline and partnerships give it opportunities to grow beyond Europe, particularly in immune-mediated dermatological diseases where demand is rising.

One important counter-factor to the upside case is that, despite improved H1 2026 revenue and margin trends, the stock’s minus 19.00% year-to-date performance indicates that investors are not yet convinced that earnings momentum will translate into sustained value creation.MarketScreener If upcoming quarters fail to confirm the H1 trajectory, the gap toward the EUR 14.30 average price target could narrow more through downward revisions than through share-price gains.

Representative product: dermatology treatments

Almirall generates a significant share of its revenue from branded prescription dermatology products targeting chronic inflammatory skin diseases. These medicines are used in conditions such as psoriasis and atopic dermatitis and often compete with biologics and small-molecule therapies from larger global pharma companies. The company’s strategy in 2026 is to deepen penetration of these drugs in key European markets and selectively expand in other regions, linking commercial roll-out to the clinical and regulatory milestones that emerge over the next few years.

Almirall stock price and market context

On its primary exchange, Bolsa de Madrid (BME), Almirall stock last closed at EUR 10.40 on September 7, 2026, with a modest daily decline of 0.19% and a year-to-date loss of about 19.00%, according to market data.MarketScreener With the average analyst target at EUR 14.30 and the share price hovering near levels last seen in summer 2022, the stock currently trades well below perceived fair value estimates, leaving room for re-rating if the company can deliver stronger margins and sustained revenue growth in upcoming quarters.